Articles
Latitude Pharma Provides 505b2 Licensing Opportunity Through Formulation Development Service
by Alex Smith expertSan Diego, CA (November 15, 2017) – The internal
product development activities of Latitude Pharma pays attention to
activities that address zones of unattended medical needs through the
right formulation development service. The activities include taking the
familiar drugs and making them considerably safer. Not just safer, they
are made easier to use and more stable and they also come up with new
intellectual property.
Being a Formulation development contract research organization,
the company makes sure that the re-formulations become eligible for the
505b2 licensing opportunity. This, in turn, helps the licensor to save a
considerable amount of time and cost when they reach FDA for approval
of their drugs.
Latitude offers the 505(b)(2) licensing
opportunity for a wide range of drug products and some of the include
Intra-V, Opti-V, Rescue-G, PumpaGon, PAC-E, DOCE-E, Nano-K, Nano-A and
24H Tramadol. Further, with the GLP formulation expertise, Latitude has
developed novel formulations of the already familiar drugs in new dose
formats.
About Latitude Pharmaceuticals Inc.:
Right
from the inception in the year 2003, Latitude Pharma has performed more
than 750 formulation development projects. The company has offered this
service for more than 200 of their client organization. This helped the
company to develop a worldwide reputation for their creative
approaches.
For more information, please visit http://latitudepharma.com
###
Sponsor Ads
About Alex Smith 
expert
196 connections, 3 recommendations, 1,352 honor points.Joined APSense since, May 14th, 2014, From laredo, United States.
Created on Nov 21st 2017 08:34. Viewed 378 times.
